Mayo Clinic Alix School of Medicine, 200 First Street SW, Rochester, MN, 55905, USA.
Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA.
Arch Dermatol Res. 2023 Nov;315(9):2721-2724. doi: 10.1007/s00403-023-02669-4. Epub 2023 Jul 21.
An inflammatory microenvironment has been shown to increase risk for malignant melanoma, suggesting that melanoma may be related to a pro-inflammatory state. Though Hashimoto's thyroiditis is one of the most common autoimmune diseases, there are no investigations of its relationship with melanoma. We aim to determine if Hashimoto's increases risk of developing melanoma. A retrospective, validated cohort of patients with a diagnosis of Hashimoto's between 2005 and 2020 were identified using the Olmsted County database. Patients were age and sex matched to controls without a Hashimoto's diagnosis. The primary outcomes were development of melanoma and time to first melanoma diagnosis. 4805 patients were included in the study, with 1726 (36%) having a diagnosis of Hashimoto's. Hashimoto's patients had no significant difference in risk of melanoma (relative risk 0.96, 95% CI 0.78-1.17) or nonmelanoma skin cancer (relative risk 0.95, 95% CI 0.86-1.06) compared with matched controls. This suggests that the local proinflammatory environment present in Hashimoto's does not contribute significantly to melanoma risk. Larger studies may be needed to further characterize the relationship between these diseases.
炎症微环境已被证明会增加恶性黑色素瘤的风险,这表明黑色素瘤可能与促炎状态有关。尽管桥本甲状腺炎是最常见的自身免疫性疾病之一,但目前尚未研究其与黑色素瘤的关系。我们旨在确定桥本甲状腺炎是否会增加患黑色素瘤的风险。本研究使用奥姆斯特德县数据库,回顾性地确定了 2005 年至 2020 年间确诊为桥本甲状腺炎的患者的验证队列。将患者按年龄和性别与无桥本甲状腺炎诊断的对照组相匹配。主要结局为黑色素瘤的发生和首次黑色素瘤诊断的时间。本研究共纳入 4805 例患者,其中 1726 例(36%)患有桥本甲状腺炎。与匹配的对照组相比,桥本甲状腺炎患者患黑色素瘤(相对风险 0.96,95%CI 0.78-1.17)或非黑色素瘤皮肤癌(相对风险 0.95,95%CI 0.86-1.06)的风险无显著差异。这表明桥本甲状腺炎中存在的局部促炎环境对黑色素瘤风险的贡献并不显著。可能需要更大的研究来进一步描述这些疾病之间的关系。